Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of CTX130 in relapsed or refractory renal cell carcinoma (COBALT-RCC) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CTX130

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: Renal Cell Carcinoma | Phase 1 | Status: TERMINATED